Analytical challenges in drug counterfeiting and falsification-The NMR approach

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 4, 2011, Pages 679-687

  Holzgrabe, Ulrike ^a   Malet Martino, Myriam ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Counterfeits; DOSY NMR; Drugs; Impurities; QNMR

Indexed keywords

HEPARIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

DRUG CONTAMINATION; DRUG QUALITY; HUMAN; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; REVIEW;

CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; COUNTERFEIT DRUGS; DRUG CONTAMINATION; HEPARIN; INTERNATIONAL COOPERATION; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; PURINES; SOLVENTS; SPECTROSCOPY, NEAR-INFRARED; SPECTRUM ANALYSIS, RAMAN; SULFONES; WORLD HEALTH ORGANIZATION; X-RAY DIFFRACTION;

EID: 79955478694     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.12.017     Document Type: Review

References (38)

1. http://www.who.int/mediacentre/factsheets/fs275/en/print.html.
2. Burki T. The real cost of counterfeit medicines. Lancet Infect. 2010, 10:585-586.
3. http://www.who.int/medicines/services/counterfeit/en/.
4. http://www.who.int/medicines/publications/pharmacopoeia/overview/en/index.html.
5. Brochure European Directorate for the Quality of Medicines and HealthCare, Strasbourg, 2010.
6. Blanco M., Villarroya I. NIR spectroscopy: a rapid-response analytical tool. TrAC 2002, 21:240-250.
7. Beckers D. X-ray beat the counterfeiters. Manuf. Chem. 2008, July/Aug:21-23.
8. NMR Spectroscopy in Pharmaceutical Analysis 2008, 157-180. Elsevier, Amsterdam. U. Holzgrabe, I. Wawer, B. Diehl (Eds.).
9. Beyer T., Holzgrabe U. Quantitative NMR spectroscopy of biologically active substances and excipients. Bioanal. Rev. 2011, 2:1-22.
10. Diehl B.W.K., Malz F., Holzgrabe U. Quantitative NMR spectroscopy in quality evaluation of active ingredients and excipients. Spectrosc. Eur. 2007, 19:15-19.
11. Quinn T.J. Primary methods of measurement and primary methods. Metrologia 1997, 34:61-65.
12. Malz F., Jancke H. Validation of quantitative NMR. J. Pharm. Biomed. Anal. 2005, 38:813-822.
13. Holzgrabe U. Quantitative NMR spectroscopy in pharmaceutical applications. Progr. NMR Spectrosc. 2010, 57:229-240.
14. Holzgrabe U. Quantitative NMR, methods and applications. Encyclopedia of Spectroscopy and Spectrometry 2010, vol. 3:2331-2339. Elsevier. 2nd ed.
15. Maniara G., Rajamoorthi K., Rajan S., Stockton G.W. Method performance and validation for quantitative analysis by 1H and 31P NMR spectroscopy. Applications to analytical standards and agricultural chemicals. Anal. Chem. 1998, 70:4921-4928.
16. Beyer T., Schollmayer C., Holzgrabe U. The role of solvents in the signal separation for quantitative 1H NMR spectroscopy. J. Pharm. Biomed. Anal. 2010, 52:51-58.
17. Holzgrabe U., Branch S.K. 1H, 19F and 13C NMR data of fifteen gyrase inhibitors and some metabolites. Magn. Res. Chem. 1994, 32:192-197.
18. Zheng G., Price W.S. Solvent signal suppression in NMR. Progr. NMR Spectrosc. 2010, 56:267-288.
19. Michaleas S., Antoniadou-Vyza E. A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements. J. Pharm. Biomed. Anal. 2006, 42:405-410.
20. Eliel E.L., Wilen S.H. Stereochemistry of Organic Compounds 1994, Wiley Interscience, New York, (Chapter 6.5).
21. NMR Spectroscopy in Pharmaceutical Analysis 2008, 269-289. Elsevier, Amsterdam. U. Holzgrabe, I. Wawer, B. Diehl (Eds.).
22. Tanner J.E. Use of stimulated echo in NMR diffusion studies. J. Chem. Phys. 1970, 52:2523-2526.
23. Pelta M.D., Barjat H., Morris G.A., Davis A.L., Hammond S.J. Pulse sequences for high-resolution diffusion-ordered spectroscopy (HR-DOSY). Magn. Reson. Chem. 1998, 36:706-714.
24. Morris K.F., Johnson C.S. Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 1992, 114:3139-3141.
25. Wu D.H., Chen A.D., Johnson C.S. An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses. J. Magn. Reson. Ser. A 1995, 115:260-264.
26. J.V. Duine (Pfizer), D. Llyod (Bristol-Myers Squibb), personal communication.
27. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.L., Shriver Z., Langer R.S., Venkataraman G., Austen F., Woodcock J., Sasisekrharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Eng. J. Med. 2008, 358:2457-2467.
28. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Sibel Gunay N., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasikheran R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
29. Beyer T., Diehl B., Randel G., Humpfer E., Schäfer H., Spraul M., Schollmayer C., Holzgrabe U. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2008, 48:13-19.
30. McEwen I., Mulloy B., Hellwig E., Kozerski L., Beyer T., Holzgrabe U., Rodomonte A., Wanko R., Spieser J.M. Determination of oversulphated chondroitin sulphate and dermatan sulphate in unfractionated heparin by 1H NMR. Pharmeur. Bio 2008, 1:31-39.
31. Alban S. Carbohydrates with anticoagulant and antithrombotic properties. Carbohydrates in Drug Design 1997, Marcel Dekker, New York, pp. 209-276. Z.J. Witczak, K.A. Nieforth (Eds.).
32. Beyer T., Matz M., Brinz D., Rädler O., Wolf B., Norwig J., Baumann K., Alban S., Holzgrabe U. Composition of OSCS-contaminated heparin occuring in 2008 in batches on the German Market. Eur. J. Pharm. Sci. 2010, 40:297-304.
33. Alban S., Lühn S., Schiemann S., Beyer T., Norwig J., Schilling C., Rädler O., Wolf B., Matz M., Holzgrabe U. Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples. Anal. Bioanal. Chem. 2011, 399:605-620.
34. Jackson G., Arver S., Banks I., Stecher V.J. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int. J. Clin. Pract. 2010, 64:497-504.
35. Poon W.T., Lam Y.H., Lai C.K., Chan A.Y.W., Mak T.W.L. Analogues of erectile dysfunction drugs: an underrecognised threat. Hong Kong Med. J. 2007, 13:359-363.
36. Balayssac S., Trefi S., Gilard V., Malet-Martino M., Martino R., Delsuc M.A. 2D and 3D DOSY 1H NMR, a useful tool for analysis of complex mixtures: application to herbal drugs or dietary supplements for erectile dysfunction. J. Pharm. Biomed. Anal. 2009, 50:602-612.
37. Trefi S., Gilard V., Balayssac S., Malet-Martino M., Martino R. The usefulness of 2D DOSY and 3D DOSY-COSY 1H NMR for mixture analysis: application to genuine and fake formulations of sildenafil (Viagra). Magn. Reson. Chem. 2009, 47:S163-S173.
38. Sitkowski J., Bednarek E., Bocian W., Kozerski L. Assessment of oversulfated chondroitin sulafte in low molecular weight and unfractionated heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J. Med. Chem. 2008, 51:7663-7665.